Clinical study shows two-drug combination can prolong survival in men with metastatic prostate cancer Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started about two drugs simultaneously, instead of delaying the next drug before cancer began to worsen, according to results of a clinical trial led simply by a Dana-Farber Cancers Institute scientist. Individuals who underwent six cycles of treatment with the chemotherapy medication docetaxel along with a hormone blocker survived for a median of 57.6 months, more than a full year longer compared to the median 44-month survival for men who received only the hormone-blocker, according to a written report in THE BRAND NEW England Journal of Medication tadapox en france .
He and Dr. Kelly will be the business lead investigators conducting the trial at NYU. Despite chemotherapy and surgery, individuals with glioblastoma multiforme brain cancer survive about 15 months typically. Even if just a small number of tumor cells are still left in the mind, that is more than enough for these fast aggressive and growing tumors to grow back again. The tumors do not grow elsewhere in your body. They recur locally but we cannot cure it. The trial will enroll individuals 18 to 65 years old with newly diagnosed glioblastoma multiforme brain cancer who will receive standard principal treatment with surgery followed by radiation with concurrent chemotherapy.